Tine Brink Henriksen

Interventional cohort study of prolonged use (>72 hours) of paracetamol in neonates: protocol of the PARASHUTE study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Sissel Sundell Haslund-Krog, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
  • ,
  • Steen Hertel, Neonatal Intensive Care Unit, Rigshospitalet, Copenhagen, Denmark.
  • ,
  • Kim Dalhoff, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
  • ,
  • Susanne Poulsen, Neonatal Intensive Care Unit, Rigshospitalet, Copenhagen, Denmark.
  • ,
  • Ulla Christensen
  • ,
  • Diana Wilkins, Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
  • ,
  • John van den Anker, Division of Pediatric Pharmacology and Pharmacometrics, Universitat Basel, Basel, BS, Switzerland.
  • ,
  • Tine Brink Henriksen
  • Helle Holst, Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark

Introduction: Anticipated or actual pain in neonates results in use of paracetamol for prolonged pain relief in many neonatal intensive care units. Clinical trials examining safety of paracetamol exposure in neonates have been of short duration (1-3 days) and hepatic biomarkers and paracetamol metabolism are rarely reported in the same studies.We aim to investigate the safety (hepatic tolerance) and effectiveness of prolonged paracetamol exposure in neonates by measuring hepatic biomarkers, plasma concentrations of paracetamol and its metabolites and pain scores. In addition, we study a possible interaction between ethanol and paracetamol.

Methods and analysis: A multicentre interventional cohort study.Neonates of any gestational age and up to 44 weeks postmenstrual age, treated with oral or intravenous paracetamol can be included.Alanine aminotransferase (ALT) and bilirubin are measured at baseline or within 24 hours after treatment initiation. P-paracetamol and metabolites are measured at steady state and every 2 days (opportunistically) together with ALT and bilirubin and lastly after discontinuation of treatment. COMFORT neo pain scores are collected longitudinally. COMFORT neo pain scores and population pharmacokinetic analysis of paracetamol samples will be analysed simultaneously using non-linear mixed effects models. One and two compartment models with first-order elimination will be tested for disposition. In addition, plasma ethanol is measured if the patient receives concomitant treatment with intravenous or oral phenobarbital containing ethanol as an excipient.

Ethics and dissemination: Inclusion of patients can be postponed 24 hours after the first paracetamol dose. This is intended to make the inclusion process less stressful for parents. This study uses standard dosing strategies. The potential risks are additional blood samples, which are collected opportunistically to reduce additional heel pricks.

Trial registrationnumber: Ethics Comittee: H-17027244, EudraCT no: 2017-002724-25, BFH-2017-106, 05952.

OriginalsprogEngelsk
Artikelnummere000427
TidsskriftBMJ paediatrics open
Vol/bind3
Nummer1
Antal sider7
ISSN2399-9772
DOI
StatusUdgivet - 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 158522679